Oligonucleotide Synthesis Market By Type (DNA Oligonucleotides, RNA Oligonucleotides), By Application (Gene Synthesis, PCR, DNA Sequencing, RNA Interference, Diagnostics, Therapeutic), By Product (Custom Oligonucleotides), By End-User (Pharmaceutical & Biotechnology Companies, Research & Academic Institutions, Diagnostic Laboratories, Contract Research Organizations), and By Region; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Oligonucleotide Synthesis Market was valued at USD 8.1 billion in 2023 and will surpass USD 19.0 billion by 2030; growing at a CAGR of 12.9% during 2024 - 2030.

The global oligonucleotide synthesis market is experiencing significant growth, driven by advancements in biotechnology and the increasing applications of oligonucleotides across various industries. Oligonucleotide synthesis involves the creation of short DNA or RNA molecules, which serve as essential tools in genetic research, diagnostics, and drug development. These synthesized molecules play a crucial role in processes such as gene synthesis, PCR (Polymerase Chain Reaction), and RNA interference. With the rise in personalized medicine, molecular diagnostics, and biopharmaceutical development, the demand for oligonucleotides is poised to grow rapidly. As the market expands, innovation in synthesis technologies and increased outsourcing of oligonucleotide synthesis are contributing to a dynamic and competitive landscape.

DNA Oligonucleotides Segment Is Largest Owing to Expanding Use in Research and Diagnostics

Among the various types of oligonucleotides, DNA oligonucleotides dominate the market due to their extensive use in research, diagnostics, and therapeutic applications. DNA oligos are essential tools in gene synthesis, PCR, DNA sequencing, and diagnostic testing, making them an indispensable component in laboratories worldwide. They are also employed in the development of gene therapies and personalized medicine, further increasing their demand. Their versatility, stability, and reliability in research applications have made DNA oligonucleotides the most widely synthesized type.

As the demand for DNA oligos grows, several companies are investing in the development of high-quality and customizable DNA oligos for applications ranging from basic research to complex clinical and diagnostic applications. DNA oligonucleotides remain the backbone of molecular biology and genetic research, contributing significantly to their market dominance. With the rise of next-generation sequencing (NGS) and gene editing technologies like CRISPR, the requirement for DNA oligonucleotides is expected to continue expanding across a variety of applications.

Gene Synthesis Application Is Fastest Growing Owing to Rising Demand for Synthetic Biology

The gene synthesis application segment is the fastest growing within the oligonucleotide synthesis market, driven by the increasing focus on synthetic biology and genetic engineering. Gene synthesis involves the assembly of long DNA molecules from short oligonucleotides, allowing researchers to design and construct genes that do not naturally exist. This process is critical for applications in drug discovery, biotechnology, and even the development of genetically modified organisms (GMOs). The growing demand for genetically engineered therapeutics, including gene therapies for rare diseases, is contributing to the rapid growth of this segment.

As the ability to synthesize genes efficiently improves, researchers are able to design complex genetic sequences more rapidly and with greater precision. The increasing availability of commercial gene synthesis services has opened new doors in the field of synthetic biology, enabling innovations in agriculture, medicine, and environmental applications. The development of personalized medicine, particularly in cancer treatments and rare genetic disorders, is another key driver for the growth of gene synthesis, making this segment highly promising for future growth.

Pharmaceutical & Biotechnology Companies End-User Segment Is Largest Due to Increased Investment in Genetic Research

The largest end-user segment in the oligonucleotide synthesis market is pharmaceutical and biotechnology companies. These companies are heavily invested in genetic research, drug development, and the manufacturing of biologic therapies, which rely on oligonucleotides for numerous applications. Pharmaceutical and biotechnology companies use oligonucleotides for gene synthesis, RNA interference (RNAi), diagnostics, and therapeutic developments. As biopharmaceuticals, such as gene therapies and mRNA vaccines, gain prominence, these companies represent the most significant source of demand for oligonucleotide products.

Moreover, the ability of oligonucleotides to serve as critical components in the development of precision medicine has spurred investment in their use. Pharmaceutical companies are increasingly focusing on targeted therapies, and oligonucleotides offer the ability to create highly specific treatments that can modify gene expression or correct genetic mutations. The growth in personalized medicine and targeted drug development has made pharmaceutical and biotechnology companies the primary consumers of oligonucleotide products.

Custom Oligonucleotides Product Is Key Driver of Market Growth

The custom oligonucleotides product segment is a major contributor to the growth of the oligonucleotide synthesis market. Custom oligonucleotides are tailored to meet the specific requirements of research, diagnostics, and therapeutic applications. These products are essential for researchers and healthcare professionals who require precision in their experiments, such as gene synthesis, PCR amplification, or RNA interference studies. Custom oligonucleotides are particularly critical for applications in gene therapy, molecular diagnostics, and CRISPR-based gene editing, where accuracy is paramount.

Custom oligonucleotides enable the synthesis of highly specific sequences for various applications, including PCR, sequencing, and drug development. The ability to offer bespoke oligonucleotides tailored to individual research projects or therapeutic needs is a key driver of market demand. This product category continues to witness significant growth as scientific research becomes more complex and the need for specialized oligonucleotide sequences expands across industries.

North America Is Largest Region Owing to Strong Research & Biotech Industry

North America remains the largest market for oligonucleotide synthesis, owing to the region's robust pharmaceutical and biotechnology sectors. The United States, in particular, has a dominant position in global biotechnology and pharmaceutical research, driving demand for high-quality oligonucleotide products. The region’s well-established infrastructure for life sciences research, along with strong funding for research and development activities, has positioned it as a leader in the market. Furthermore, the prevalence of diseases that require genetic research and the high demand for precision medicine contribute to the region’s leadership in the oligonucleotide synthesis market.

In addition to the U.S., Canada is also witnessing growth in biotechnology and genomics research, further boosting the demand for oligonucleotides. The growing emphasis on personalized medicine and gene therapies in North America continues to be a key factor in the region's dominance, with the ongoing advancements in gene editing technologies, such as CRISPR, driving the need for custom oligonucleotides.

Competitive Landscape and Leading Companies

The oligonucleotide synthesis market is highly competitive, with several key players dominating the landscape. Companies like Thermo Fisher Scientific, Integrated DNA Technologies, and Merck Group’s Sigma-Aldrich are leading the market, offering a range of oligonucleotide products and services. These companies are known for their expertise in synthesizing high-quality oligonucleotides for a variety of applications, including gene synthesis, PCR, and RNA interference. Their strong global presence, extensive product portfolios, and established reputations in biotechnology and pharmaceuticals make them the dominant players in the market.

The competitive environment is characterized by ongoing innovations in oligonucleotide synthesis technology, with companies constantly striving to improve synthesis efficiency, reduce costs, and offer higher-quality products. Additionally, partnerships, mergers, and acquisitions are common as companies aim to expand their capabilities and market reach. With the increasing demand for customized oligonucleotides, companies are also investing heavily in improving their manufacturing processes and providing tailored solutions to meet specific research and therapeutic needs.

Recent Developments:

• Thermo Fisher Scientific expanded its portfolio in diagnostics and oligonucleotide synthesis through the acquisition of The Binding Site Group, strengthening its molecular diagnostics and life sciences offerings.
• Sigma-Aldrich and Bio-Techne formed a strategic partnership to advance oligonucleotide synthesis technologies, aimed at enhancing both research and clinical applications of oligos.
• Integrated DNA Technologies unveiled a new high-throughput platform for custom oligonucleotide synthesis, aimed at increasing the efficiency of large-scale DNA and RNA production for research purposes.
• Eurofins Genomics announced the expansion of its oligonucleotide synthesis capabilities with a new state-of-the-art facility in the U.S., meeting the growing demand for custom oligos in the pharmaceutical sector.
• Twist Bioscience entered into a partnership with Roche to enhance oligonucleotide-based drug discovery and synthetic biology applications, combining Roche's expertise in pharmaceutical development with Twist's advanced gene synthesis technology.

List of Leading Companies:

• Agilent Technologies, Inc.
• Beckman Coulter, Inc.
• Bioneer Corporation
• Biosearch Technologies, Inc.
• DNA Script
• Eurofins Genomics
• GE Healthcare Life Sciences
• Illumina, Inc.
• Integrated DNA Technologies, Inc.
• Kaneka Eurogentec S.A.
• OriGene Technologies, Inc.
• Sigma-Aldrich (Merck Group)
• Telesis Bio, Inc.
• Thermo Fisher Scientific, Inc.
• Twist Bioscience

Report Scope: